Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate 1: Corporate VC Invests in Repurposed Drugs and New Combinations in CNS and Respiratory Diseases

27 Apr

The venture capital arm of a global pharmaceutical firm invests in early stage ideas with breakthrough technologies addressing major unmet medical needs. The firm seeks to make equity investments in Seed and Series A/B rounds with an ultimate possibility of acquisition. The firm has a global mandate and is currently seeking new investment opportunities.

The firm is currently seeking to invest in early to mid-stage repurposed drugs, repositioned drugs, combination therapies, and new delivery technologies and devices for old drugs. In terms of indications, the firm is focused on CNS and respiratory diseases. The firm will prioritize 505(b)(2) opportunities.

The firm seeks companies with a strong and experienced management team. The firm may take a board seat/board observer rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 2: European PE Fund Invests Opportunistically in Drugs and Devices

27 Apr

A private equity firm based in Paris, France has a venture team that currently has €400M AUM. The firm mainly provides equity financing and may provide convertible loans as follow-on investments. The firm typically makes an initial investment of up to €2-3M, and up to €8M over the life of the investment, which can be start as early as seed stage. The firm preferably invests in European-based companies, and seeks to make about 2 allocations every year in the life sciences area (minority stakes).

The firm remains opportunistic in the life sciences, with a focus on drug development and medical devices. The firm is agnostic in terms of subsectors, indications and stage. Currently, the firm is active in many subsectors.

The firm seeks to acquire minority stakes in its portfolio companies. The firm is looking for companies with a talented and entrepreneurial management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 3: US Private Equity Firm Makes Multi-Stage Investments in Biotech and Medtech

27 Apr

A private equity group with offices on the US East and West Coasts has over $1 billion in assets under management, and is investing from a third fund of over $500 million. The firm makes both venture-stage and growth-stage equity investments, which are typically in the $10-30 million range. The firm primarily invests in North America and the European Union but may also consider opportunities in the Middle East.

The firm invests in biotechnology, medical technology, diagnostics, healthcare services, and healthcare IT. The firm is generally agnostic regarding indications. The firm invests at a range of stages, from development through to profitability, but prefers to back technologies that have attained proof of concept data.

The firm invests in both pre-revenue companies and post-revenue companies. The firm typically leads or co-leads investments, and prefers to take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 4: Healthcare Company Looking to In-License or Acquire Innovative Late Stage Drugs and Devices

27 Apr

A specialist healthcare company with offices in Europe, North America, and Australia is actively looking to in-license and acquire innovative therapeutics and medical devices that are of strategic interest. The firm is capable of making allocations ranging from £10 million to over £100 million and more for later-stage acquisitions. The firm is most interested in companies that are looking to be marketed in the United States although they are open to global opportunities as well.

The firm is interested in therapeutic assets and medical devices, particularly interventional medicine products that can be used to advance the treatment of cancer, cardiovascular, and pulmonary diseases. The firm is open to therapeutics within these areas as well as other indications, pending they are intended to be hospital products. The firm is primarily interested in small molecule therapeutics and is focused on late-stage/marketed products at the current time.

For medical devices, the firm is looking for companies that have 510K approval in oncology, vascular and pulmonary fields. The firm’s current device products include interventional oncology products used to treat patients with liver tumors, interventional vascular products used to treat patients with severe blood clots, and investigational devices for the treatment of severe emphysema.

The firm is interested in working with founding management teams prior to investment and is open to in-licensing from public and private clients.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 1: Family Office Invests in Growth Stage Healthtech and Health Service Companies

20 Apr

A family office located in New York makes approximately 2 to 3 equity investments per year into healthcare companies located in the United States. The firm does not have an average investment size as it depends on the opportunity, however – the firm looks to take a control seat when doing so as they are a value added investor.

The firm is interested in services, HCIT, diagnostics, medical devices, and auxiliary services. The firm is very opportunistic within these areas and they are agnostic with regard to indication areas. The firm looks for growth stage companies located in the United States that are generating profits or close to doing so. The firm is not interested in long term deals and prefers companies with 48 months of an exit.

The firm has no explicit management team requirements as the firm is a value-added investor and takes an active role in its portfolio companies. The firm requests a board seat and provides its portfolio companies with experienced talent to help improve operations.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 2: Canadian Venture Capital Focuses on Software-Enabled Devices, Wearables and Hospital Efficiency

20 Apr

A Toronto-based venture capital firm seeks to make 4-5 new investments per year, and typically co-invests in seed, venture and series A investments at $200,000 – $1M per company. The firm has partnerships with medical software/device, fintech and ICT funds in which the firm will pass on deal flow. The firm has particular preference to companies located in North America, though is open to Australia and Western Europe depending on the opportunity, and does not request distribution rights for international investments.

The firm is interested in early-stage wearable technology and software-enabled technology, particularly ones that can improve hospital operations. The firm does not have a preference for any specific indication areas. The firm does not have revenue requirements for wearable technology and is not particularly interested in products that require regulatory pathways. The firm is interested in companies that are in the development or clinical-stage but will only invest in healthcare IT companies if it is already established with positive cash flow. Outside of software and wearable technology, the firm will look at medical devices to evaluate and connect to partnered funds.

The firm values sweat equity but the firm will not make any investments into a company unless the founding team has invested their own funds into the company’s success. The firm takes a board seat when making any new investments and looks for strong, experienced management teams. The first question the firm will ask any new opportunity is whether or not they have experience in marketing, sales, startups, or the industry they are entering. The firm can provide strategic management if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 3: Pharma Firm Seeks Novel Drugs in Blood Cancers, Pediatric Diseases and Sleep Disorders

20 Apr

A pharma firm headquartered in Europe, with offices in the U.S. and across Europe, forms in-licensing relationships and partnerships with development-stage pharmaceutical companies. The firm is open to partnering with companies globally.

The firm is focused on hematology-oncology, and sleep disorders. The firm is also interested in reviewing assets in pediatric oncology, niche areas of CNS and other rare disorders, particularly pediatric diseases. The firm generally prefers that assets that have obtained proof of concept in humans, but may look at earlier stage opportunities in the firm’s key areas of hematology-oncology or sleep disorders.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com